Product Description
Guanabenz belongs to the general class of medicines called antihypertensives. It is used to treat high blood pressure (hypertension). (Sourced from: https://www.mayoclinic.org/drugs-supplements/guanabenz-oral-route/description/drg-20064106)
Mechanisms of Action: ADRA2A Agonist,ADRA2B Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Germany | New Zealand | Peru | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PROMISE | P2 |
Active, not recruiting |
Amyotrophic Lateral Sclerosis |
2018-10-28 |